Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

INFU vs DXR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

INFU Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 5–5 Matrix Metrics)

INFU Overall Winner 6-Pillar Tally: INFU 5 – 1 DXR Matrix Metrics: INFU 5 – 5 DXR

As of Nov 16, 2026, InfuSystem Holdings, Inc. (INFU) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). INFU carries a Unified Composite Score of 36.6/100 (SELL) at $14.79 (26.4x Forward P/E, 8.5% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin).

  • Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. INFU 36.6/100 SELL), INFU captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.5% vs. -5894.3% operating margin) and revenue trajectory (+3.0% vs. +25.5% YoY).
  • Technical & Structure Timing Caution: INFU trades in a Markup technical trend (CONSOLIDATION options phase, RSI 59.9); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About INFU vs DXR
INFU NYSE American Head-to-Head Winner
InfuSystem Holdings, Inc.
Surgical & Medical Instruments & Apparatus
$14.79
+0.48% 1D
Market Cap $294.9M
TTM Revenue $144M
Forward P/E 26.4x
Beta / 30D Vol 0.78β · 48% Vol
Unified Composite Score
36.6 / 100 SELL
Tech 8.0 Fund 28.0 Flow 54.0 Mom 25.9
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (6.3% over 20 days), RSI 60
RSI-14: 59.9 · SMA20: $14.18 · SMA50: $13.44
DXR NASDAQ
Daxor Corporation Common Stock
Surgical & Medical Instruments & Apparatus
$8.36
-1.47% 1D
Market Cap $49.5M
TTM Revenue $31,360
Forward P/E 64.5x
Beta / 30D Vol 0.28β · 32% Vol
Unified Composite Score
52.2 / 100 HOLD
Tech 52.0 Fund 59.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -5.2%), weak momentum, RSI 31
RSI-14: 31.2 · SMA20: $8.91 · SMA50: $10.07

6-Pillar Scorecard Institutional Category Breakdown (INFU 5 – 1 DXR)

Columns: Metric · INFU · DXR
1. Valuation Multiples INFU
Forward P/E 26.4x 64.5x
Trailing P/E 33.5x 7.7x
PEG Ratio 1.73x N/M
EV / Revenue 2.1x N/M
2. Growth & Scale DXR
Revenue Growth (YoY) +3.0% +25.5%
Earnings Growth (YoY) +36.4% +329.3%
TTM Revenue (USD) $144M $31,360
Market Cap $294.9M $49.5M
3. Profitability & Quality INFU
Gross Margin 57.6% 100.0%
Operating Margin 8.5% -5894.3%
Net Profit Margin 6.5% 19861.4%
Return on Equity (ROE) 15.8% 14.2%
4. Balance Sheet & Cash Flow INFU
Cash Generation (TTM) $13M N/A
Cash Flow Margin 9.2% N/A
Net Cash / Leverage $13M Net Debt (0.35x D/E) $8.88 Book/Sh · 14.2% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning INFU
Options Structure Phase CONSOLIDATION UNCLASSIFIED
Current IV / %ile 47.0% (7th %ile) N/A (N/A)
Put/Call OI Skew 2.74x (Put-Skewed) N/A
OBV Trend / Tech Phase ACCUMULATION · Markup NEUTRAL · Markdown
6. R&D & Supply-Chain Moat INFU
OpEx & R&D Intensity 49.1% of Rev ($71M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: INFU (5) vs DXR (5)
Institutional Metric INFU DXR Criterion Row Edge
Market Capitalization
Scale
$294.9M $49.5M Larger Scale INFU
Trailing P/E Ratio
Valuation
33.5x 7.7x Lower Multiple DXR
Forward P/E Ratio
Valuation
26.4x 64.5x Lower Multiple INFU
Revenue Growth (YoY)
Growth
+3.0% +25.5% Higher Growth DXR
Operating Margin (TTM)
Profitability
8.5% -5894.3% Higher Margin INFU
Net Profit Margin
Profitability
6.5% 19861.4% Higher Margin DXR
Return on Equity (ROE)
Capital Efficiency
15.8% 14.2% Higher ROE INFU
52-Week Range Position
Momentum
92% ($7–$15) 2% ($8–$15) Stronger Trend INFU
Beta / 30D Volatility
Risk Regime
0.78β · 48% Vol 0.28β · 32% Vol Lower Realized Risk DXR
Unified Institutional Score
Composite Signal
36.6 / 100 (SELL) 52.2 / 100 (HOLD) Higher Composite DXR
Trailing 12M Revenue (USD)
Operating Scale
$144M $31,360 FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
57.6% 100.0% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
1.73x PEG · 2.1x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$13M ($13M Net Debt (0.35x D/E)) N/A ($8.88 Book/Sh · 14.2% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon INFU +27.24 pp
INFU: +10.37% · DXR: -16.87%
3M Horizon INFU +38.17 pp
INFU: +18.51% · DXR: -19.66%
6M Horizon INFU +59.79 pp
INFU: +42.35% · DXR: -17.44%
1Y Horizon INFU +78.84 pp
INFU: +45.57% · DXR: -33.27%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on INFU vs DXR. Trailing 12-month operating profitability (INFU 8.5% vs DXR -5894.3%) and valuation multiples (INFU 26.4x vs DXR 64.5x Forward P/E) are benchmarked directly in Pillar 4 below.

INFU ADR TTM Benchmark FX-Normalized USD
TTM Revenue$144M
Gross Margin57.6%
Op. Margin8.5%
ROE / Fwd P/E15.8% · 26.4x
DXR ADR TTM Benchmark FX-Normalized USD
TTM Revenue$31,360
Gross Margin100.0%
Op. Margin-5894.3%
ROE / Fwd P/E14.2% · 64.5x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
INFU CONSOLIDATION
22d in phase · OBV ACCUMULATION
Current IV 47.0%
IV Percentile 7th %ile
Put/Call OI Skew 2.74x (Put-Skewed)
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact INFU Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DXR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact DXR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
INFU Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $294.9M market capitalization and 8.5% operating margin.
OpEx & R&D Reinvestment 49.1% of Rev ($71M)
90D Engineering Disclosures 0 Published
DXR Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $49.5M market capitalization and -5894.3% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ INFU vs DXR Key Questions & Quantitative Answers

As of Nov 16, 2026, InfuSystem Holdings, Inc. (INFU) is the stronger overall head-to-head candidate over Daxor Corporation (DXR) in the Tradestie Institutional Equity Comparison Engine, winning 5–5 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). INFU carries a Unified Composite Score of 36.6/100 (SELL) at $14.79 (26.4x Forward P/E, 8.5% operating margin), whereas DXR carries 52.2/100 (HOLD) at $8.36 (64.5x Forward P/E, -5894.3% operating margin). Composite vs. Pillar Nuance: While DXR currently prints a higher short-term Unified Composite Score (52.2/100 HOLD vs. INFU 36.6/100 SELL), INFU captures the overall institutional head-to-head verdict (5–5 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (8.5% vs. -5894.3% operating margin) and revenue trajectory (+3.0% vs. +25.5% YoY). Technical & Structure Timing Caution: INFU trades in a Markup technical trend (CONSOLIDATION options phase, RSI 59.9); meanwhile DXR is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 31.2). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DXR leads the Growth & Scale pillar: INFU posts +3.0% YoY revenue growth and +36.4% YoY earnings growth on $144M TTM revenue (57.6% gross margin, 8.5% operating margin), compared with DXR at +25.5% YoY revenue growth and +329.3% YoY earnings growth on $31,360 TTM revenue (100.0% gross margin, -5894.3% operating margin). On trailing 12-month operating scale, INFU generates $144M in USD-normalized revenue versus $31,360 for DXR. In operating R&D and SG&A reinvestment, INFU deploys 49.1% of Rev ($71M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DXR.

INFU screens cheaper on headline valuation multiples. INFU trades at 26.4x Forward P/E, 33.5x Trailing P/E, 1.73x PEG, and 2.1x EV/Revenue (9.2% FCF margin), whereas DXR trades at 64.5x Forward P/E, 7.7x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against INFU (15.8% ROE) versus DXR (14.2% ROE) capital efficiency.

In options market volatility and institutional positioning, INFU carries 47.0% implied volatility (7th %ile, Compressed (<25th %ile)), a 2.74x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (0.78β · 48% Vol realized risk). By comparison, DXR carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.28β · 32% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.